235 related articles for article (PubMed ID: 31903239)
1. The prognostic value of tumor mutation burden in
Jiao XD; He X; Qin BD; Liu K; Wu Y; Liu J; Hou T; Zang YS
J Thorac Dis; 2019 Nov; 11(11):4507-4515. PubMed ID: 31903239
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
Jiao XD; Qin BD; You P; Cai J; Zang YS
Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
[TBL] [Abstract][Full Text] [Related]
4. The co-mutation of
Zhang Y; Li S; Lyu Z; Cai J; Zheng N; Li Y; Xu T; Zeng H
J Thorac Dis; 2022 Jan; 14(1):185-193. PubMed ID: 35242380
[TBL] [Abstract][Full Text] [Related]
5. The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs.
Gu W; Liu P; Tang J; Lai J; Wang S; Zhang J; Xu J; Deng J; Yu F; Shi C; Qiu F
Front Oncol; 2023; 13():1288468. PubMed ID: 38375203
[TBL] [Abstract][Full Text] [Related]
6. A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in
Xiang L; Fu X; Wang X; Li W; Zheng X; Nan K; Tian T
Front Oncol; 2020; 10():559896. PubMed ID: 33072585
[TBL] [Abstract][Full Text] [Related]
7. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with
Fu J; Li Y; Li C; Tong Y; Li M; Cang S
Transl Cancer Res; 2021 Sep; 10(9):3963-3978. PubMed ID: 35116695
[TBL] [Abstract][Full Text] [Related]
8. Genomic landscape and prognosis of patients with
Fan Z; Zhang Q; Feng L; Wang L; Zhou X; Han J; Li D; Liu J; Zhang X; Zuo J; Zou X; Cai Y; Sun Y; Wang Y
Ann Transl Med; 2022 Feb; 10(4):188. PubMed ID: 35280362
[TBL] [Abstract][Full Text] [Related]
9. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
10. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with
Offin M; Rizvi H; Tenet M; Ni A; Sanchez-Vega F; Li BT; Drilon A; Kris MG; Rudin CM; Schultz N; Arcila ME; Ladanyi M; Riely GJ; Yu H; Hellmann MD
Clin Cancer Res; 2019 Feb; 25(3):1063-1069. PubMed ID: 30045933
[TBL] [Abstract][Full Text] [Related]
11. Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors.
Wen Y; Lin A; Zhu W; Wei T; Luo P; Guo L; Zhang J
Front Pharmacol; 2021; 12():645862. PubMed ID: 34163353
[No Abstract] [Full Text] [Related]
12. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
13. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
[TBL] [Abstract][Full Text] [Related]
14. Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
Tian HX; Chen ZH; Jie GL; Wang Z; Yan HH; Wu SP; Zhang SL; Lu DX; Zhang XC; Wu YL
Cancer Med; 2023 Jan; 12(1):396-406. PubMed ID: 35702826
[TBL] [Abstract][Full Text] [Related]
15. Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in
Li T; Pang X; Wang J; Wang S; Guo Y; He N; Xing P; Li J
Front Oncol; 2021; 11():591922. PubMed ID: 34136375
[TBL] [Abstract][Full Text] [Related]
16. Investigation of
Cao Y; Lan D; Ke X; Zheng W; Zeng J; Niu N; Fu C; Deng W; Jin S
Heliyon; 2024 Jun; 10(11):e32287. PubMed ID: 38912481
[TBL] [Abstract][Full Text] [Related]
17. Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma.
Wang H; Chen S; Meng D; Wu C; Zhu J; Jiang M; Ning J; Wu S; Wu L; Li J; Chen B; Zhao S; Li W; Yu J; Fang Q; Zhu J; Zhao W; He Y; Zhou C
Onco Targets Ther; 2021; 14():2953-2965. PubMed ID: 33976553
[TBL] [Abstract][Full Text] [Related]
18. Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma.
Koh YW; Park B; Jung SH; Han JH; Haam S; Lee HW
Front Immunol; 2023; 14():1137880. PubMed ID: 37033978
[TBL] [Abstract][Full Text] [Related]
19. MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma.
Bai L; Huo R; Fang G; Ma T; Shang Y
Front Oncol; 2023; 13():1055122. PubMed ID: 36756152
[TBL] [Abstract][Full Text] [Related]
20. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
Wang Z; Wang C; Lin S; Yu X
Front Oncol; 2021; 11():725292. PubMed ID: 34513703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
